JNJ
USDJohnson & Johnson Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$186.830
Máximo
$187.820
Mínimo
$185.620
Volume
5.00M
Fundamentos da empresa
Capitalização de mercado
450.2B
Setor
Drug Manufacturers - General
País
United States
Estatísticas de negociação
Volume médio
8.39M
Bolsa de valores
NYQ
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Kenvue’s legal risks loom over planned acquisition by Kimberly-Clark
Kimberly-Clark said on Monday it plans to acquire Band-Aid maker Kenvue , even as the latter company faces thousands of lawsuits involving its painkiller Tylenol and talc-based baby powder, raising questions about the scope of the liabilities Kimberly-Clark might inherit.
Kimberly-Clark’s $50 billion leap into health and beauty tests investor faith
Kimberly-Clark's nearly $50 billion offer for Tylenol maker Kenvue is a risky bet that the world's biggest consumer market, the United States, will keep growing even as lower-income shoppers trim their budgets, according to analysts.
Kimberly-Clark agrees to buy Kenvue in $48.7 billion deal, creating consumer staples giant
The combined company would bring together brands like Huggies and Kleenex with the likes of Band-Aid and Tylenol.
Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized...
Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks
The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit hyperactivity disorder.
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare...
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
Johnson & Johnson (NYSE: JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational...
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.